CHI's Eighth Annual World Pharmaceutical Congress. Targeting pain with novel therapeutics: Part 1.
Foster
Keith
K
Syntaxin Ltd, The Quadrant, Abingdon, Oxon, UK. keith.foster@syntaxin.com
D000581:Amidohydrolases / Q000037:antagonists & inhibitors / Q000235:genetics; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D063386:Cannabinoid Receptor Agonists; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D055786:Gene Knockout Techniques; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D058914:Purinergic Antagonists; D020917:Receptor, trkA / Q000037:antagonists & inhibitors; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000700:Analgesics; D063386:Cannabinoid Receptor Agonists; D015507:Drugs, Investigational; D058914:Purinergic Antagonists; D020917:Receptor, trkA; D000099252:Fatty Acid Amide Hydrolases